Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
The addition of CDK4/6 inhibitors has broken the five-year barrier in median overall survival (OS) in metastatic HR positive breast cancer.
This review highlights rising breast cancer incidence, racial disparities, and the need for effective risk reduction strategies.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC
- Development of Herceptin resistance in breast cancer cells